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PC conditioning, high-dose sirolimus, and pre-emptive T-
Rapa DLI is a very safe method of achieving allo-engraftment
without substantial conditioning toxicity or acute GVHD.
However, this approach yielded split, mixed chimerism,
which was not conducive to GVT effects against refractory
RCC. The remarkable safety and minimal intensity of this
platform make it an attractive transplant approach for non-
malignant disorders but will require modiﬁcations aimed at
promoting GVT effects in malignant disorders.410
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Introduction: Although administration of G-CSF to healthy
donors for mobilization and collection of peripheral blood
stem cell (PBSC) is common in adult volunteers, there are
limited data on short-and especially long-term efﬁcacy in
healthy pediatric donors, notably due to ethical issues. The
purpose of this study was to assess the short- and long-
term adverse effects of using G-CSF in pediatric sibling
donors.
Methods: Healthy pediatric sibling (age15 years) donors of
PBSCwhose parents were reluctant to donate stem cells from
bone marrow (BMSC) were enrolled in this prospective
study. Written informed consent was obtained from all the
children’s parents before entering the transplantation pro-
gram. G-CSF (Neupogen, Roche, Switzerland) was admin-
istered at 5mg/kg once daily for 3 consecutive days and twice
on the fourth day. Questionnaires were used to assess the
health status of donors.
Results: 104 healthy pediatric donors of PBSCs aged 2.5-15
years (median age: 10 years) were followed for a median of
1527 days (393-4621 days). The most common short-term
side effects were headache (n¼4) and fatigue (n¼2). None of
the mentioned medical problems worsened after G-CSF in-
jection. Two pregnancies after the administration of G-CSF
resulted in normal births. No malignancy or death was
reported.
Discussion: To best of our knowledge, this is the ﬁrst
investigation on a large number of healthy pediatric donors
to assess long-term effects of PBSC donation. Our study in-
dicates PBSC collection, using G-CSF could be a safe and
effective method for healthy pediatric donors whose par-
ents are reluctant to allow their child to undergo collection
of bone marrow because of concerns over side effects of
anesthesia. Further studies with larger sample size are
required to determine the safety of using G-CSF in healthy
children.411
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Pathology, Mount Sinai Medical Center, New York, NYBackground: Donor cell leukemia (DCL) is a rare complica-
tion of transplantation. In 1971, Fialkow reported the case of
a female patient with ALL who relapsed after a transplant
from her brother. Cytogenetics showed only donor derived
XY metaphases. Sporadic cases of DCL have since been re-
ported, however, the precise incidence remains unclear. An
EBMT review of 10489 allogeneic transplants found an inci-
dence ofw0.1%.
Case Report: A 41-year-old-man was admitted 567 days
after a double unrelated blood cord transplantation (UBCT)
for B-ALL. He received reduced-intensity conditioning
prior to his UBCT with cyclophosphamide 50 mg/kg, ﬂu-
darabine 200 mg/m2, and 200 cGy TBI (Cy/Flu/TBI). GVHD
prophylaxis included CSA and MMF. Post-transplant, bone
marrow (BM) and peripheral blood (PB) chimerism was
100% donor.
On day+515 post-transplant he was thrombocytopenic
with 8% blasts. A BM biopsy revealed a donor derived AML,
with 22% blasts. BM chimerism remained 100% donor. He
received decitabine at 20mg/m2 for 10 days. Post-treatment
BM biopsy was negative for AML.
On day+567, he was admitted with fever, pleuritic
chest pain and tachycardia. EKG demonstrated T-wave
inversions in V3-V5. Both troponin (1.8 ng/ml) and BNP
(805 pg/ml) were elevated. Chest CT revealed a circum-
ferential pericardial and nodular soft tissue densities
posterior to the heart and he ultimately underwent a
pericardectomy.
The pericardial pathology showed myeloid sarcoma. The
tumor cells were CD43+, MPO focal+, CD34 focal+, CD117
focal+, CD68weak+, CD163 focal+, PAX5-, CD56-, TdT-, CD79a
focal weak+ by immunohistochemistry. The chimerism
revealed that the lesion was entirely donor derived. A BM
biopsy showed no evidence of AML with normal hemato-
poiesis and full donor chimerism. Thus, cardiac myeloid
sarcoma represented an isolated site of disease.
Unfortunately, the patient continued to deteriorate and
expired on day+579.
Discussion:Within DCL, isolated donor derived granulocytic
sarcoma, as in our patient, is an extremely rare and chal-
lenging diagnosis. Reactive donor leukocytes can inﬁltrate a
host derived granulocytic sarcoma making it difﬁcult to
distinguish relapse from a DCL.
Given the comparatively recent introduction of UCBT,
fewer cases of cord blood associated DCL leukemia have
been reported in the literature when compared with PBSCT
or BMT. Some interesting trends have emerged. AML is the
most common type of UCBT DCL. There is a shorter interval
to the development of DCL in UCBT (median of 14.5
months) compared to BMT or PBSCT (36 months).
Abnormal karyotypes, particularly monosomy 7, are more
common in UCBT DCL. Perhaps, UCB is uniquely sensitive
to leukemogenic effects of conditioning. Given the pre-
dominance of AML DCL in UCBT, more cases of donor
myeloid sarcoma may emerge. Improved molecular testing
will allow precise detection and avoid mistakenly catego-
rizing DCL as relapsed disease.412
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Figure 1. Impact of ABO incompatibility on OS of 143 AML/MDS patients who
underwent RIC allo HCT.
Figure 2. Impact of HLA matching on OS in 146 AML/MDS patients who un-
derwent RIC allo HCT.
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Background: Reduced intensity conditioning (RIC) has
expanded allogeneic hematopoietic stem cell transplantation
(HCT) to elderly patients and to those with additional
comorbidities. There is inconclusive evidence suggesting
that the risk of adverse events, such as pure red cell aplasia
(PRCA), delayed engraftment, or shortened survival, is
increased with ABO incompatibility. We sought to better
elucidate these issues.
Methods: After IRB approval, consecutive patients with
myeloid neoplasms (MDS and AML) who underwent their
ﬁrst RIC allo HCT from 2005 to 2014 were identiﬁed. All
clinical and transplant data were retrospectively abstracted.
Conditioning regimens, GVHD prophylaxis and transfusions
were according to institutional standards.
Results: Of 148 patients (median age 61, male 62%), 97 (65%)
had AML, 29 (20%) had MDS with excess blasts and 22 (15%)
had MDS without excess blasts. At last follow up, 31(21%)
relapses and 63 (48%) deaths were noted (median follow up
17 months).
Transfusion and engraftment data are shown in Table 1.
PRCA was diagnosed in 6 (20% of the major mismatch
group), all of whom had an A to O mismatch. ABO major
mismatches had higher RBC and PLT transfusion needs at
100 days (p<0.0001 for RBC and 0.004 for PLT transfusion),
and at 1 year (p¼0.004 for RBC and 0.007 for PLT trans-
fusion), as well as delayed RBC (p<0.001) and PLT
(p<0.001) engraftment compared with the ABO compat-
ible group. This was true even after excluding patients
with PRCA. PMN engraftment was not affected by ABO
compatibility.
Therewasnodifference inoverall survival (OS) among the3
groups (p¼0.51) (Figure1). For the total cohort,mediandisease
free survival (DFS) and OS estimates were 43 and 44 months,
respectively. Relapse rate (RR) was 22%, and non-relapse
mortality (NRM)was21%at theendof1year.Acuteandchronic
GVHDwere seen in 58% and 59%, respectively. After univariate
and multivariate analyses, the only factors with impact on OS
were the degree of HLAmatching (p¼0.005) (Figure 2) and the
presence of chronicGVHD (p<0.0001) (Figure 3). Therewas no
difference in DFS (p¼0.97) or OS (p¼0.78) between patients
with AML and MDS.
Conclusions: Our analysis of a large cohort of AML/MDS
patients who underwent RIC allo HCT shows that ABO
incompatibility hasno impactonDFS,OS, RR,NRM, or acute and
chronic GVHD. However, higher RBC and PLT transfusion needs,
and PRCA are frequent complications adding to the morbidity.Table 1
Transfusion and engraftment data according to ABO compatibility groups in
148 AML/MDS patients who underwent RIC allo-HSCT
Total patients: 148* ABO
Compatible
(n[89)
Major
Mismatch
(n[29)
Minor
Mismatch
(n[25)
P.
Value
Median RBC units
100 days 3 12 2 <0.0001
1 year 5 17.5 3.5 0.002
Median PLT units
100 days 3.5 10 3 0.008
1 year 5 15 4 0.013
Median days to
engraftment
RBC 11 29 9 <0.0001
PLT 11 14 11 0.003
PMN 18 19 16 0.091
* Bidirectional ABO mismatches (n¼5) were not included in the analysis
Figure 3. Impact of chronic GVHD (cGVHD) on OS in 138 AML/MDS patients
who underwent RIC allo HCT.413
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